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ABSTRACT
Purpose: Increasing numbers of haematology cancer survivors warrants identification of the most
effective model of survivorship care to survivors from a diverse range of haematological cancers
with aggressive treatment regimens. This review aimed to identify models of survivorship care to
support the needs of haematology cancer survivors.
Methods: An integrative literature review method utilised a search of electronic databases
(CINAHL, Medline, PsycInfo, PubMed, EMBASE, PsycArticles, Cochrane Library) for eligible
articles (up to July 2014). Articles were included if they proposed or reported the use of a model
of care for haematology cancer survivors.
Results: Fourteen articles were included in this review. Eight articles proposed and described
models of care and six reported the use of a range of survivorship models of care in haematology
cancer survivors. No randomised controlled trials or literature reviews were found to have been
undertaken specifically with this cohort of cancer survivors. There was variation in the models
described and who provided the survivorship care.
Conclusion: Due to the lack of studies evaluating the effectiveness of models of care, it is
difficult to determine the best model of care for haematology cancer survivors. Many different
models of care are being put into practice before robust research is conducted. Therefore welldesigned high quality pragmatic randomised controlled trials are required to inform clinical
practice.

Key Words: models of care; survivorship; haematological cancer; nurse-led; shared care; followup care.
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INTRODUCTION
Internationally, survivorship care is recognised as a priority in the cancer care continuum.
This has been principally guided by the Institute of Medicine (IOM) report in 2005, From
Cancer Patient to Cancer Survivor: Lost in Transition [1]. By 2008, sixteen European countries
had defined national cancer plans, but to date very few have survivorship services operating [2].
The National Coalition for Cancer Survivorship [3] defines survivorship as the experience of
living with, through and beyond a diagnosis of cancer and includes the impact on family, friends
and caregivers. It is recognised throughout the literature, based on the IOM essential components
of survivorship care, that survivorship care should include the following components [4, 5]:


Prevention; screening and interventions for recurrence, long-term and late effects; early
detection of new cancers;



Assessment, support, management and information provision of physical, psychological,
social and spiritual needs;



Monitoring, information, and promotion of healthy living behaviours and disease prevention;



Coordination of care between providers to communicate overall health needs.
Current conventional models of survivorship care, including routine follow-up, predominately

focus on surveillance for recurrence and monitoring of physical side effects, rather than
provision of supportive care, health promotion, late effects monitoring and surveillance for new
cancers [6, 7]. With an increasing awareness that communication between health care
professionals and patients is suboptimal and that information provided to patients and primary
care providers at treatment completion is often inadequate [8, 9], there is a growing movement to
redesign how survivorship follow-up care is delivered. Furthermore, cancer patients frequently
experience multiple health problems earlier than the general population [10], suggesting a need
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for early and ongoing, comprehensive approaches to management designed to promote and
support patient participation in maximising recovery.
Haematology cancer patients are underrepresented and understudied in survivorship care [11]
despite international figures indicating an increase in five year relative survival rates [12]. The
most common haematological cancers are leukaemias, lymphomas and multiple myelomas
(MM) [13]. Each of these has distinctive and complex treatment regimens that commonly
involve aggressive high dose chemotherapy agents, and/or targeted therapies, radiotherapy and
haematopoietic stem cell transplants [14]. Unfortunately, the consequence of largely aggressive
treatment includes long-term and late physical, practical and psychosocial effects which include:
fear of recurrence; fertility; relationship; financial; employment and insurance issues [15-17]. A
qualitative study on specialist-led follow-up with haematology cancer survivors reported a lack
of preparation and support in finding information and resources with poor continuity of care as
patients transitioned into the survivorship phase [18]. These patients therefore may require
models of survivorship care with specific components that differ from those designed for the
more common cancers (breast, prostate and colorectal).
Two systematic reviews [19, 20] and a literature review [6] on survivorship models of care
have been recently published. Sussman et al. [20] reviewed 12 randomised controlled trials
(RCTs) and four systematic reviews. De Leeuw, Larsson [6] reviewed 21 nurse-led follow-up
studies and Howell et al. [19] evaluated 10 practice guidelines and nine RCTs. All primary
outcomes in the reviewed studies were related to recurrence detection and in some cases healthrelated quality of life and/or patient satisfaction [6, 19, 20]. Importantly, all studies included
cancers with similar trajectories of care (breast, prostate, colon) making generalisations to other
complex cancers such as haematological cancers difficult. Therefore, the haematology focus of
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this integrative literature review will add to the limited body of knowledge currently available in
this cohort of survivors.
This integrative literature review undertook an analysis of the literature to examine the
following questions:
1. What are the common attributes of survivorship models of care developed generally for
cancer patients and specifically for haematology cancer patients?
a. What resources (human, financial, tools, care plans) are required to support these
models of care?
b. What are the potential benefits and shortfalls of these models of care?
c. What outcome measures have been used to evaluate these models of care and what
are the findings?

METHOD
The integrative literature review method was chosen as the theoretical framework to
guide this review. It is structured according to five stages: problem formulation; literature search;
data evaluation; data analysis and presentation. This allows for an in-depth evaluation of the
issues encompassing the empirical, theoretical and clinical approaches within a structured
systematic methodology [21].

PROBLEM FORMULATION
To date, the term ‘Model of Care’ (MOC) has not been well defined in published
literature. In this review, MOC, as defined by the Robert Wood Johnson Foundation [22], is a
conceptual outline of how to plan all current and future facility and clinical services to guide and
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direct a patient’s experience within a health care system. Essential elements of any MOC
include: a clear identification of health professionals responsible for planning and coordination
of care; care delivery setting [20]; promotion of health maintenance; effective illness
interventions; and establishing and evaluating expected clinical outcomes [23]. The medical
specialist has traditionally led haematology cancer care follow-up, however other models of
cancer survivorship follow-up are now emerging [24]. Therefore the focus of this integrative
literature review was to identify models of care used by health care providers to ensure quality
survivorship follow-up for haematology cancer survivors.

LITERATURE SEARCH
The primary search utilised the following electronic databases: Cumulative Index to
Nursing and Allied Health Literature (CINAHL); Medline; PsycInfo; PubMed; EMBASE;
PsycArticles and Cochrane Library from earliest records to July 2014. Combinations of the
following search terms were used: (model of care or follow-up or nurse-led or shared care or
primary care provider-led or General Practitioner-led or oncology-led or end of treatment or post
treatment) and (survivorship or cancer survivor or survivorship care) and (cancer or neoplasm or
oncology) and (haematology or leukaemia or lymphoma or multiple myeloma). A hand search of
the reference lists from full text articles was correspondingly employed. Searches were restricted
to the English language, humans and adults. Inclusion criteria used were: clinician experiences of
MOC for the post treatment phase of haematological cancer; articles that reported on models of
care; and articles that reported on the structure of survivorship services. Exclusion criteria were:
studies with less than a 50% haematology cancer patient / haematologist cohort; studies that
reported MOC for patients who received curative surgery only (i.e. no chemotherapy and/or
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radiotherapy treatment); studies reporting MOC from child, adolescent or adult survivors of a
childhood cancer; non-cancer MOC studies; MOC studies that lacked provider of survivorship
care information; and opinion papers, letters, editorials, commentaries, conference abstracts,
conference proceedings or case studies.

DATA EVALUATION STAGE
Abstract titles were reviewed by one author [KT] to assess eligibility. A summary of the
selection process [25] is provided in Figure 1. The initial search yielded 2907 abstracts.
Following removal of duplicate articles and screening using the exclusion and inclusion criteria,
61 full-text articles were retrieved. Of these, 14 articles met the inclusion criteria and were
included in this review. Methodological characteristics documented included: authors;
publication year; country; study design; model; provider; disease; years post treatment; sample
size and response rate; resources required; potential benefits; potential deficits; outcome
measures; results and level of evidence developed by Melynyk, Fineout-Overholt [26] shown in
Table 1. Due to variations in study population and methodologies used, meta-analysis was not
possible.

RESULTS
Study characteristics
No systematic reviews of haematology cancer survivorship models of care were found. In
total, 14 articles were included in this review. Eight articles described and proposed different
models of survivorship care [27, 28, 1, 5, 29, 30, 9, 7] (Table 2). An additional six articles
reported the use of a range of models of care for haematology cancer survivors: two reported
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nurse-led studies [31, 32] and four referred to physician-led studies [33, 8, 34, 35] (Table 3). The
included articles reported views from Australia (n=1), United States of America (USA) (n=10)
and United Kingdom (UK) (n=3), shown in Table 3. The eight articles that described and
proposed various models of survivorship care were categorised into three main settings: hospitalbased; primary care-based and shared care and included models, providers, and characteristics.
The results are shown in Table 2. These included articles used multiple terms to describe
clinicians. For clarity, the following terms have been used: primary care provider (PCP) to
denote community-based general practitioners (GP) or family physicians; specialist to represent
the main hospital consultant oncologist (medical, radiation, surgical) or haematologist; and nurse
which includes nurse specialist, nurse practitioner (NP) or nurse coordinator.
Of the six studies that reported the use of specific models of survivorship care, four were
quantitative and two were qualitative studies. Studies reflected moderate (IV) to low (VI) levels
of evidence.

DATA ANALYSIS AND PRESENTATION
Cancer survivorship MOC
The first component of this integrative literature review was to identify different models
of survivorship care (Table 2). Characteristically, hospital based follow-up care is commonly
specialist-led, with often no end point [27, 29]. Survivors may acquire an impression the
specialist has become their primary carer, particularly if they have assessed and treated comorbid conditions during the treatment phase [7]. Multidisciplinary disease-specific clinics [5, 9,
7] and survivorship clinics were most often a one-time consultation for an assessment, plan of
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follow-up care provision and referrals to other health care providers [1, 30]. Clinics within this
framework frequently consulted on one aspect of post treatment care, such as late effects [9].
Nurse-led survivorship clinics, as described, were mostly hospital based and delivered a
number of interventions including: information; symptom management; psychosocial support;
allied health referrals and health promotion strategies [27]. They can involve longer
consultations and more frequent patient contact [27, 6]. PCP-led models involved a complete
transition of all care from the hospital specialist to PCP [28, 5, 9]. This can be challenging for
specialists who decide to transition care, as the level of knowledge and experience amongst PCPs
can differ [5, 30].
Shared care models involved more than two providers sharing care and responsibility [1,
9]. According to Oeffinger, McCabe [7], after treatment completion, the PCP assumes
responsibility for: maintenance of survivor health; management of any co-morbid conditions;
ongoing physical and psychosocial concerns; and health promotion. The medical specialist
provides a survivorship care plan and treatment summary and ongoing consultation for
recurrence or problematic late effects if required. Both providers are to undertake monitoring,
therefore a clear delineation of responsibility for particular screening and surveillance is
important [5]. Landier [5] identified shared care as appropriate for low risk and even some
moderate risk patients, however intensively treated patients (i.e. haematological cancers) require
specialist monitoring.

Nurse-led
The two studies that evaluated nurse-led follow-up in lymphoma survivors predominately
targeted late effects and health promotion. Gates et al. [31] studied a nurse-led component of a
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haematology late effects survivorship multidisciplinary team, whereas John, Armes [32] reported
on nurses replacing specialist-led follow-up, independently delivering comprehensive
survivorship care. Both clinics assessed for supportive care needs and concerns and delivered
health promotion and information [31, 32]. John, Armes [32] provided an annual clinic with
nurse contact details, whereas Gates et al. [31] delivered four consultations over a six month
period. Both studies measured different outcomes and utilised different comparative groups,
thereby making them difficult to compare, especially as Gates et al. [31] has only published
preliminary results. John, Armes [32] prospective comparative study of 61 patients concluded
that patient satisfaction was equivalent in the nurse-led clinic cohort compared with the medicalled clinic cohort and was in some cases preferred. However, the number in each group was not
reported and it is possible patient satisfaction was related more to the decrease in wait times. It
would likewise be difficult to attribute lifestyle changes to the clinic as patients were seen
annually.

Physician-led
The included physician-led studies (n=4) presented comparisons of self-reported
practices in survivorship follow-up [8] and clinician perceptions of survivorship follow-up [3335]. A qualitative exploratory study by Chubak et al. [33] reported the views of clinicians and
administrators (n=40) from 10 integrated cancer centres. All respondents reported shared care
was being practised. This was based on the assumption that all survivors have a PCP, and despite
respondents reporting a lack of standard approaches to sharing care between clinicians. Support
for survivorship-specific care appeared lacking, with 22% (n=9) observing it would not add to
current care and may decrease care integration. The authors concluded that interviewing
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respondents from sites without survivorship care would give an unbiased account. However,
there may have been a lack of awareness related to the benefits of survivorship care.
Dicicco-Bloom, Cunningham [8] qualitatively assessed the feasibility of a shared care
survivorship model with 21 primary care clinicians. The overall perception was that primary
carers are already involved in survivor follow-up, despite poor information provision from
specialists. They perceived electronic medical records are often inaccessible. The authors further
concluded survivorship care plan reasearch is limited. PCPs felt excluded once patients entered
the hospital system, especially when follow-up extended well past treatment, to healthy patients
with no recurrent cancer. This was reflected in the study by Greenfield et al. [35] who reported
the views of clinicians (n=475) regarding long-term follow-up and found only 5% (n=14) of
haematology cancer survivors are discharged after two years, and only 42% (n=45 lymphoma)
and 32% (n=10 leukaemia) are discharged after five years. This finding may be explained by the
complex and ongoing late effect sequelae in haematology patients and their expectation of longterm specialist follow-up. Although respondent numbers were not reported, it was perceived that
long-term specialist follow-up gave survivors false reassurance and perpetuated the illness role.
Whereas the PCP-led model was perceived as normalising the survivors’ experience, with a
corresponding increase in co-morbid disease management. The authors concluded by proposing a
risk stratification process whereby low risk survivors are transitioned early to PCP and high risk
survivors stay within the hospital model or become part of a shared care model supported by
survivorship care plans.
Frew et al. [34] studied survivor (n=626) and clinican (n=2302) views on different
models of care. Respondents could choose from a number of follow-up models, but were not
asked if they would reject a particular model. What was evident in the study by Frew et al. [34]
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was specialist follow-up was the most experienced by survivors (84% n=528) and clinicians
(95% n=2167). However specialists who had experienced non-specialist models of follow up
(60% n=819) preferred this model over all others including specialist-led (87%).

DISCUSSION
Deciding upon a model of survivorship follow-up care for haematology cancer survivors
is difficult due to the considerable variability between the types of haematological cancers, range
of treatment regimens and long-term and late effects that impact the survivorship phase of the
cancer continuum [17]. For haematology cancer survivors, different models have been proposed
and utilised. However, we are unable to determine the best or the most appropriate model. This
finding is consistent with those of Campbell et al. [36], reporting that no model was identified as
better than any others. The reasons for these findings are that most of the articles were not
evaluative in nature, and do not allow comparison. Patients who have only received a single
model of care would not be able to comment on potential benefits of other models of care,
therefore further research in understanding survivors’ perspectives of follow-up care is required.
The transition of survivor care to the PCP requires PCP willingness. A study involving
PCP views reported the willingness to accept exclusive care for lymphoma patients was three
years after treatment completion [37]. This may be due to the complex nature and length of the
treatment regimens [15] and a lack of tumour specific follow-up protocols used by
haematologists [35]. With a lack of guidance and comprehensive information communicated
from the haematologist [8, 35], PCPs may be reluctant to accept exclusive care of what they
perceive as complex and ‘high risk’ patients [37]. Shared care maybe more satisfatory to
haematologists, survivors and PCPs as it encompasses the strengths and expertise of providers
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from more than one discipline. As a study of follow-up care providers has reported, a high
proportion of survivors are followed up by multiple providers [38]. Therefore, it is important that
good coordination and communication is in place to reduce the possibility of either incomplete or
duplication of services between multiple providers. Cooper et al. [27] proposed that patients’
transition into survivorship phase and out to primary care through specialist nurses so that
monitoring for recurrence, psychosocial needs and health promotion are addressed and
communicated to survivors and health care providers. This too has implications with John,
Armes [32] demonstrating that increased nurse workload occurred with patients utilising
telephone contact between the scheduled clinic visits.
Establishing survivorship care provision will require careful planning and robust
prospective evaluations. It is important to note that coordinated survivorship care interventions
are complex interventions [39] and can be resource intensive, requiring robust evaluations using
patient and system outcomes. This integrative review identified the three models of care:
physician-led, nurse-led and shared care models. Ultimately, high quality pragmatic RCTs are
required to test the effectiveness of these models. There is an urgent need for health research
funders to understand the need for good survivorship cancer care and fund the development and
evaluation of the effects of various models of survivorship care.
To the best of our knowledge, this review is the first that examines the characteristics,
resources required and effectiveness of survivorship care models specifically for patients with
haematological cancer. A number of limitations of this review are acknowledged. The search
revealed only a relatively small number of articles that met the inclusion criteria. Furthermore,
the variation of study methodology, range of measures, populations and follow-up approaches
made it difficult to compare models of care and enabled only tentative conclusions [31, 32].
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Additionally, short-term follow-up or the timing of interventions may have been insufficient to
report whether different models have impacted survivorship care. Finally, an inherent bias in
interpretation might be due to the evaluator.

CONCLUSION
There is a paucity of effectiveness research related to haematology cancer survivors and
specifically models of survivorship care in this cohort. Shared care models have been suggested
as an alternative to exclusive specialist care. For shared care to work effectively ongoing
communication channels need to be established and maintained. Nurse-led models have been
proposed as another feasible model, where a specialist nurse intervenes directly and acts as the
conduit between patient, hospital-based treatment team and PCP. However, more research is
needed to define how these models should be best configured and evaluated for their
effectiveness. For future development, a haematology-specific survivor-based needs assessment
tool, individualised treatment summary and survivorship care plan would be integral. These
would assist in guiding survivor-centred screening, health promotion and identification of needs
to be monitored and managed. This approach may address many of the barriers that have been
postulated.
Future research will need to account for increasing cancer incidence and survival rates,
making extensive specialist follow-up care more difficult to maintain for new patients and
survivors. To provide quality survivorship care, new and innovative models of haematology
survivorship follow-up are required that address the need for long-term follow-up that accounts
for potential late treatment effects, risks of secondary cancers, development of treatment related
co-morbid conditions and psychosocial well-being. This review revealed a lack of high quality
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evidence suggesting the effectiveness of any single model of care. A well-designed pragmatic
randomised controlled trial, assessing patient and system outcomes including costs, is required to
inform clinical practice.

Conflict of interests: The authors declare no conflicts of interest relevant to this manuscript.
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Studies included in
qualitative synthesis
N=17

Fig. 1 Flowchart of literature search results

2671 abstracts excluded

44 articles excluded
No distinction between treatment
and survivors in follow-up
evaluated (n=2)
No model of care or follow-up
evaluated (n=22)
Perception rather than experience
of a survivorship MOC (n=8)
Less than 50% haematological
cancer survivors (n=12)
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Table 1 Levels of Evidence
Level
Evidence
I

Systematic review of all relevant randomised controlled trials

II

At least one well designed randomised controlled trial

III

Well-designed controlled trials without randomisation

IV

V

Well-designed cohort studies, case control studies, interrupted time series with a
control group, historically controlled studies, interrupted time series without a
control group or with case- series
Systematic reviews of descriptive and qualitative studies

VI

Single descriptive and qualitative studies

VII

Expert opinion from clinicians, authorities and/or reports of expert committees
or based on physiology
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Table 2 Existing or Proposed Models of Cancer Survivorship Care
Setting
Model
Provider
Model Characteristics
Hospital

Multidisciplinary
survivorship clinic
[7]

Oncologist, network of
consulting physicians,
oncology or
haematology nurse
practitioner (NP),
psychologist, social
worker










Consultative clinic
[27, 29]

Specialist

Consultative clinic
[7]

Specialist

Survivorship
follow-up clinic
[30,1]

Late effects clinic
[9]

Can be consultative or ongoing
Multiple providers seen at same visit
Complex and resource intense
Co-morbid and treatment related conditions can
be addressed
Can be extension of care, embedded in treatment
team
Disease-specific specialist defines follow-up
plan
NP follow-up who communicates with PCP to
initiate shared care
Large patient cohort needed



Ongoing (rarely Oncologist takes on primary
carer role)





One-time comprehensive visit
Treatment summary and survivorship care plan
Review of recommendations – surveillance,
screening, health promotion







Separate from routine care
Holistic assessment of survivor
End of treatment or on maintenance therapy
Treatment summary, survivorship care plan and
individualised information provision
Can have telephone follow-up

Nurse and/or specialist



Haematology / Oncology treatment centres

Oncology nurse or NP



Comprehensive, long-term follow-up to assess,

Specialist

25
Nurse-led [27, 1]

Primary
Care

General
survivorship clinic
[28, 5]

Nurse collaboration
with practice specialist
PCP (i.e. breast care
PCP)







and provide primary care needs
ASCO surveillance recommendations used
Clinic and/or telephone follow-up
Referral for services or refers to specialists

Full transition to PCP after treatment completion
Can have communication from specialist: late
PCP-led [9]
PCP
effects management and surveillance
 Usually low risk for recurrence or late effects
Shared
Shared care
Specialist & PCP
 Oncologist for oncology related issues
Care
[1, 7]
 PCP for co-morbidities, other cancer screening
and prevention
ASCO American Society of Clinical Oncology; NP Nurse practitioner; PCP primary care physician
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Table 3 Methodological Characteristics of Models of Haematological Cancer Survivorship Care (n=6)
Author
Study
MOC
Disease
Resources
Potential
Potential
Design
Required
Benefits
Deficits
Year
Provider
Years Post
Treatment
Country
Sample Size
(Response
Rate %)
Chubak et
Exploratory Shared care
10 Cancer
Survivorshi Time and
Clearer
al. [33]
study
Research
p care plan
lack of
evidence to
SemiNetwork sites (SCP) specialists
support
2012
structured
only 5
to followsurvivorshi
telephone
Cancer types
responders
up
p care
USA
interviews
not identified
identified
survivors
needed
use of
40/48 (83%)
6/10 sites
Administrator Support
survivor
s / clinical
groups
specific
leaders
tools not
/providers in
being used
oncology,
primary care

Outcome
Measures

Results

Level of
Evidence

Perspectives
on: survivors
needs;
current
survivorship
practices;
barriers;
areas for
future
research

Only 2/10 sites
had formal
survivorship
programs (1
nurse-led, 1
physician
assistant-led)

VI

Responses for
survivorship care
needs: address
fear recurrence
35%; information
on long-term
effects 40%;
nutritional and
exercise support
27%;
psychosocial
support 62.5%
Overall
uncertainty about
best models of
survivorship care
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DiCiccoBloom &
Cunningha
m [8]
2013
USA

In-depth
interviews
on
information
sharing
to/from
specialist &
patients

Shared care

21 Primary
care clinicians
(PCC) (11
PCP & 10 NP)

Electronic
medical
records
access

Unknown
patient types
or
survivorship
period

SCP

Primary
care
perspective
Information
sharing
ensures
effective
care
transitions

No
guidelines
or
consensus
for many
cancers on
screening,
surveillanc
e, late
effects (LE)

Understand
nature of
interactions
between
primary care,
specialist &
patient

Absence
systematic
information
sharing among
PCP, patient,
specialist

VI

Some patients
continue to see
PCC during
treatment
Reliance on
patients to
provide clinical
information from
specialist (not
always reliable
for complex
conditions /
treatment)
Academic
hospital settings
were worst in
communication to
PCC

Frew et al.
[34]
2010

Compariso
n survey on
models of
follow up

Models
presented for
perception &
experience:

Cancer
diagnosis or
treatment not
disclosed

Nil
described

Nonspecialist
models
tend to

Survey did
not ask for
survivor
diagnosis &

Perceptions
of reasons
for followup; levels of

SCP effect on
patient outcomes limited evidence
Reasons for
IV
follow-up:
monitoring for
early
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hospital based;
telephone;
non-specialist;
group; patient
managed; no
follow-up

UK

provide
more
psychological
support

Range to over
10 years
626 (21%)
survivors/care
rs

treatment
which may
alter model
preference
Survey did
not ask if
any models
would be
rejected so
potential
deficits not
identified

940 (32%)
PCP
804 specialists
(including
haematologist
s) 558 nurses
/allied health
(47%)

preference
for different
follow-up
models;
effect of
individual
experience
on follow-up
model
preference

complications;
detecting
recurrence;
detecting LE,
providing
information &
support (70%)
Preference for
model of followup experienced:
86% survivors
preferred hospital
based follow-up
and was
experienced most
(84%)
Clinicians had
experience of
more models of
follow-up

Gates et al.
[31]

Quasiexperiment
al

Late effects
MDT
(haematologist

HL
5 years

Education
package

Health
promotion

SCP not
given until
2nd visit (at

Primary
outcome:
health

Specialists
endorsed nonspecialist or
patient managed
follow-up (87%)
PCP endorsed
hospital based and
patient managed
follow-up (83%)
No final
IV
published results
from this study
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2012
Australia

comparison
healthy
cohort
versus
Hodgkin
lymphoma
(HL)
survivors

, transplant
physician,
radiation
oncologist,
cardiologist,
endocrinologis
t, primary care
liaison,
psychologist,
LE social
worker, LE
CNC)

30 HL + 30
healthy
participants
(91%)

Nurse-led
clinic for
health
promotion: 2
visits + 2
phone calls

Greenfield
et al. [35]
2009
UK

E-survey
comparison
of clinician
views on
long-term
follow-up

PCP-led

Screening
tools
(Late
Effects
Supportive
Care Needs
Screening
Tool; The
General
Health
Index; The
Health
Promoting
Lifestyle
Profile II)
SCP copy
to survivor /
PCP

18-45 year old
breast,
lymphoma,
leukaemia, or
germ cell
survivors
> 2 years
421 cancer
clinicians
(36%
haematologist,
33%

Communica
tion
Specialist
nurse
support
(91% most
important
resource)
Risk
stratificatio
n - low risk
to PCPs,

Psychosoci 4 months)
al issues
identified
& resources
and support
given
Importance
of
surveillanc
e
Survivor
sees all
relevant
providers
on same
day

Specialists
can focus
on acute
care
Lower
costs

Potential
loss of
outcome
data, LE
information
to
specialists

PCP:
existing
relationship
with
survivor;
accessible;

PCP: Lack
expertise in
survivorshi
p issues,
increases
survivor

promotion
intervention
from nurse to
improve HL
survivors
knowledge
and
motivation to
adopt health
promoting
behaviours
Secondary
outcomes:
improved
perception of
health status;
reduced LE
unmet needs;
reduced LE
worry
Compare
long-term
follow-up:
reasons for
follow-up;
advantage /
disadvantage
of PCP-led
follow-up;
current
practice;
resources
and support
required

Anecdotal
analysis shows
appreciation of:
SCP; screening
assessment

Specialists rated
clinical reasons
for follow-up
higher
Nurses and PCP
rated both clinical
& supportive
reasons higher
Reasons for
follow-up: PCP
rated recurrence
(96%)
Specialists rated

IV

30
oncologist,
18% surgeon,
10% nurse,
2% other)
54 PCP

John &
Armes [32]
2013
UK

Prospective
comparison
specialistled versus
nurse-led

high risk
hospital
follow-up
SCP &
Treatment
summary
(TS)

convenient;
knowledge
of local
support;
expertise in
chronic
health

Survivorship
follow-up
clinic

Lymphoma

2 CNS

3 years

Information
prescription

Nurse-led
(replaces
specialist
follow-up)

50 notes
audited (25
per group)

Written
information
provision

120 survivors
(60 per group)
assessed wait
time

Holistic
needs
assessment
Monitoring
for late
effects
Health
promotion

61 (82%)
survivors
assessed
patient
satisfaction
(unclear split
medical-led
versus nurseled)

Longer
consultatio
ns

Post
treatment
contact

anxiety,
time
issues

LE (76%)
recurrence (71%)
Haematologist
use of follow-up
protocol for
leukaemia and
lymphoma 19%

No tumour
specific
follow-up
guidelines

Annual
clinic visit

Documenta
tion

Preferred
clinic not
assessed

Wait time
Patient
satisfaction

Discharge to PCP:
5% at 2 years
42-32% by 5
years
Documentation
IV
improved – 50%
of psychological
& sexual issues
still not recorded
Wait times
reduced from
average 65 mins
(specialist) to 10
mins (Nurse)
Nurse-led was
equal to
specialist-led
clinic and
preferred in some
areas
Nursing telephone
workload
increased
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CNC Cancer Nurse Consultant; CNS Cancer Nurse Specialist; HL Hodgkin Lymphoma ; LE Late effects; MDT multi-disciplinary team; MM multiple
myeloma; NHL Non-Hodgkin Lymphoma; NP Nurse practitioner; PCP primary care provider; SCP survivorship care plan; TS treatment summary

